F
Frits van Rhee
Researcher at University of Arkansas for Medical Sciences
Publications - Â 380
Citations - Â 17235
Frits van Rhee is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 61, co-authored 323 publications receiving 14983 citations. Previous affiliations of Frits van Rhee include Washington University in St. Louis & Medical College of Wisconsin.
Papers
More filters
Journal ArticleDOI
The molecular classification of multiple myeloma
Fenghuang Zhan,Yongsheng Huang,Yongsheng Huang,Simona Colla,Simona Colla,James P. Stewart,James P. Stewart,Ichiro Hanamura,Ichiro Hanamura,Sushil K. Gupta,Sushil K. Gupta,Joshua Epstein,Joshua Epstein,Shmuel Yaccoby,Shmuel Yaccoby,Jeffrey R. Sawyer,Jeffrey R. Sawyer,Bart Burington,Bart Burington,Elias Anaissie,Elias Anaissie,Klaus Hollmig,Klaus Hollmig,Mauricio Pineda-Roman,Mauricio Pineda-Roman,Guido J Tricot,Guido J Tricot,Frits van Rhee,Frits van Rhee,Ronald Walker,Ronald Walker,Maurizio Zangari,Maurizio Zangari,John Crowley,John Crowley,Bart Barlogie,Bart Barlogie,John D. Shaughnessy +37 more
TL;DR: A subset of cases with a predominating myeloid gene expression signature had more favorable baseline characteristics and superior prognosis to those lacking this signature, suggesting that this signature is linked to disease progression.
Journal ArticleDOI
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy,Fenghuang Zhan,Bart Burington,Yongsheng Huang,Simona Colla,Ichiro Hanamura,James P. Stewart,Bob Kordsmeier,Christopher Randolph,David R. Williams,Yan Xiao,Hongwei Xu,Joshua Epstein,Elias Anaissie,Somashekar G. Krishna,Michele Cottler-Fox,Klaus Hollmig,Abid Mohiuddin,Mauricio Pineda-Roman,Guido Tricot,Frits van Rhee,Jeffrey R. Sawyer,Yazan Alsayed,Ronald C. Walker,Maurizio Zangari,John Crowley,Bart Barlogie +26 more
TL;DR: The data suggest that altered transcriptional regulation of genes mapping to chromosome 1 may contribute to disease progression, and that expression profiling can be used to identify high-risk disease and guide therapeutic interventions.
Journal ArticleDOI
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
Bart Barlogie,Guido Tricot,Elias Anaissie,John D. Shaughnessy,Erik Rasmussen,Frits van Rhee,Athanasios Fassas,Maurizio Zangari,Klaus Hollmig,Mauricio Pineda-Roman,Choon Kee Lee,Giampaolo Talamo,Raymond Thertulien,Elias Kiwan,Somashekar G. Krishna,Michele Fox,John Crowley +16 more
TL;DR: When incorporated into high-dose therapy for myeloma, thalidomide increased the frequency of complete responses and extended event-free survival at the expense of added adverse effects without improving overall survival.
Journal ArticleDOI
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
Fenghuang Zhan,Johanna Hardin,Bob Kordsmeier,Klaus Bumm,Mingzhong Zheng,Erming Tian,Ralph D. Sanderson,Yang Yang,Carla S. Wilson,Maurizio Zangari,Elias Anaissie,Christopher Morris,Firas Muwalla,Frits van Rhee,Athanasios Fassas,John Crowley,Guido Tricot,Bart Barlogie,John D. Shaughnessy +18 more
TL;DR: Novel candidate MM disease genes have been identified using gene expression profiling and this profiling has led to the development of a gene-based classification system for MM.
Journal ArticleDOI
CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Eric D. Hsi,Roxanne Steinle,Balaji Balasa,Susann Szmania,Aparna Draksharapu,Benny P. Shum,Mahrukh Huseni,David M. W. Powers,Amulya Nanisetti,Yin Zhang,Audie Rice,Anne van Abbema,Melanie Wong,Gao Liu,Fenghuang Zhan,Myles B.C. Dillon,Shihao Chen,Susan Rhodes,Franklin Fuh,Naoya Tsurushita,Shankar Kumar,Vladimir Vexler,John D. Shaughnessy,Bart Barlogie,Frits van Rhee,Mohamad A. Hussein,Daniel E. H. Afar,Marna Williams +27 more
TL;DR: It is suggested that HuLuc63 eliminates myeloma cells, at least in part, via NK-mediated ADCC and shows the therapeutic potential of targeting CS1 with Hu Luc63 for the treatment of multipleMyeloma.